Chemotherapy Use, Performance Status, and Quality of Life at the End of Life (2015)

Peer-Reviewed Study · Prigerson HG, Bao Y, Shah MA, et al. · September 2015

Prigerson HG et al., 2015-09: Prospective cohort of 312 patients with progressive metastatic cancer followed to death at six US oncology clinics. Chemotherapy near death did not prolong survival and, among patients with good performance status, was associated with worse quality of dying (OR 0.35).

Among patients with good (ECOG score = 1) baseline performance status, chemotherapy use compared with nonuse was associated with worse QOD (odds ratio [OR], 0.35; 95% CI, 0.17-0.75; P = .01).

p.778 (Abstract, Results)

Prigerson HG et al., 2015-09: Prospective cohort of 312 patients with progressive metastatic cancer followed to death at six US oncology clinics. Chemotherapy near death did not prolong survival and, among patients with good performance status, was associated with worse quality of dying (OR 0.35). Funding and author disclosures are not captured in the MEDLINE record; the article is PMC4828728 and its funding/COI section did not return through automated clients. No drug maker involved (observational). Comparator: no chemotherapy at the same performance-status level, adjusted. The finding is conditional and the paper says so: no QOL difference at ECOG 2 or 3. Study type: controlled study.